- $1.57bn
- $4.85bn
- $4.25bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.14 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 10.26% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.63 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 14.58 | ||
| Price to Sales | 0.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.09% | ||
| Return on Equity | -52.57% | ||
| Operating Margin | -36.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,138.7 | 4,451.6 | 4,655.6 | 4,373.4 | 4,253.1 | 4,056.37 | 4,098.55 | 0.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -68.66 | n/a | n/a | n/a | n/a | n/a | +13.35 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.
Directors
- Rolf Classon NEC (76)
- Murray Kessler PRE (61)
- Raymond Silcock CFO (71)
- Robert Willis CHO (52)
- Thomas Farrington EVP (63)
- Todd Kingma EVP (61)
- Svend Andersen EVP (59)
- James Dillard EVP (57)
- Ronald Janish EVP (55)
- Sharon Kochan EVP (53)
- Grainne Quinn EVP (51)
- Bradley Alford IND (64)
- Orlando Ashford IND (52)
- Katherine Doyle IND (53)
- Adriana Karaboutis IND (58)
- Jeffrey Kindler IND (64)
- Erica Mann IND (62)
- Donal O'Connor IND (70)
- Geoffrey Parker IND (56)
- Theodore Samuels IND (66)
- Last Annual
- December 31st, 2025
- Last Interim
- March 28th, 2026
- Incorporated
- June 28th, 2013
- Public Since
- December 17th, 1991
- No. of Shareholders
- 4,053
- No. of Employees
- 8,100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New York Stock Exchange
- Shares in Issue
- 138,367,770

- Address
- THE SHARP BUILDING HOGAN PLACE, DUBLIN 2, DUBLIN, D02 TY74
- Web
- https://www.perrigo.com/
- Phone
- +353 17094000
- Contact
- Eric Jacobson
- Auditors
- Ernst & Young LLP
Latest News for PRGO
Upcoming Events for PRGO
Dividend For P1RG34.SA - 1.0872 BRL
Dividend For PRGO.N - 0.2900 USD
Similar to PRGO
Abbvie
New York Stock Exchange
AstraZeneca
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
FAQ
As of Today at 04:38 UTC, shares in Perrigo are trading at $11.35. This share price information is delayed by 15 minutes.
Shares in Perrigo last closed at $11.35 and the price had moved by -57.82% over the past 365 days. In terms of relative price strength the Perrigo share price has underperformed the S&P500 Index by -66.91% over the past year.
The overall consensus recommendation for Perrigo is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Perrigo dividend yield is 10.22% based on the trailing twelve month period.
Last year, Perrigo paid a total dividend of $1.16, and it currently has a trailing dividend yield of 10.22%.Looking ahead, shares in Perrigo are due to go ex-dividend on 2026-05-29 and the next dividend pay date is 2026-06-16.
Perrigo are due to go ex-dividend on 2026-05-29 and the next dividend pay date is 2026-06-16. The historic dividend yield on Perrigo shares is currently 10.22%.
To buy shares in Perrigo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $11.35, shares in Perrigo had a market capitalisation of $1.57bn.
Here are the trading details for Perrigo:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: PRGO
Based on an overall assessment of its quality, value and momentum Perrigo is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Perrigo is $15.50. That is 36.56% above the last closing price of $11.35.
Analysts covering Perrigo currently have a consensus Earnings Per Share (EPS) forecast of $2.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Perrigo. Over the past six months, its share price has underperformed the S&P500 Index by -19.14%.
As of the last closing price of $11.35, shares in Perrigo were trading -27.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Perrigo PE ratio based on its reported earnings over the past 12 months is 5.14. The shares last closed at $11.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Perrigo's management team is headed by:
- Rolf Classon - NEC
- Murray Kessler - PRE
- Raymond Silcock - CFO
- Robert Willis - CHO
- Thomas Farrington - EVP
- Todd Kingma - EVP
- Svend Andersen - EVP
- James Dillard - EVP
- Ronald Janish - EVP
- Sharon Kochan - EVP
- Grainne Quinn - EVP
- Bradley Alford - IND
- Orlando Ashford - IND
- Katherine Doyle - IND
- Adriana Karaboutis - IND
- Jeffrey Kindler - IND
- Erica Mann - IND
- Donal O'Connor - IND
- Geoffrey Parker - IND
- Theodore Samuels - IND





